JP2022548778A5 - - Google Patents
Info
- Publication number
- JP2022548778A5 JP2022548778A5 JP2022518209A JP2022518209A JP2022548778A5 JP 2022548778 A5 JP2022548778 A5 JP 2022548778A5 JP 2022518209 A JP2022518209 A JP 2022518209A JP 2022518209 A JP2022518209 A JP 2022518209A JP 2022548778 A5 JP2022548778 A5 JP 2022548778A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- fap
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962904340P | 2019-09-23 | 2019-09-23 | |
| US62/904,340 | 2019-09-23 | ||
| PCT/US2020/052227 WO2021061778A1 (en) | 2019-09-23 | 2020-09-23 | Disrupting tumor tissues by targeting fibroblast activation protein (fap) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548778A JP2022548778A (ja) | 2022-11-21 |
| JP2022548778A5 true JP2022548778A5 (enExample) | 2023-09-06 |
| JP7621344B2 JP7621344B2 (ja) | 2025-01-24 |
Family
ID=74881688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518209A Active JP7621344B2 (ja) | 2019-09-23 | 2020-09-23 | 線維芽細胞活性化タンパク質（ｆａｐ）を標的とすることによる腫瘍組織の破壊の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12116418B2 (enExample) |
| EP (1) | EP4034554A4 (enExample) |
| JP (1) | JP7621344B2 (enExample) |
| KR (1) | KR20220066312A (enExample) |
| CN (1) | CN114746438A (enExample) |
| AU (1) | AU2020353000A1 (enExample) |
| BR (1) | BR112022005423A2 (enExample) |
| CA (1) | CA3151550A1 (enExample) |
| IL (1) | IL291342A (enExample) |
| MX (1) | MX2022003466A (enExample) |
| WO (1) | WO2021061778A1 (enExample) |
| ZA (1) | ZA202203511B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019067425A1 (en) | 2017-09-26 | 2019-04-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES |
| MX2022003465A (es) | 2019-09-23 | 2022-06-16 | Univ Pennsylvania | Anticuerpo monoclonal contra proteína de activación de fibroblasto canino de reacción cruzada con proteína de activación de fibroblasto (fap) de ratón y humana. |
| US12116418B2 (en) | 2019-09-23 | 2024-10-15 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| CN116348604A (zh) * | 2020-08-10 | 2023-06-27 | 克莱格医学有限公司 | 多功能的免疫效应细胞及其应用 |
| AU2022277649A1 (en) * | 2021-05-21 | 2023-11-30 | Cellectis S.A. | Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors |
| AU2023290273A1 (en) * | 2022-06-14 | 2024-12-12 | Purdue Research Foundation | Car-expressing pluripotent stem cell-derived neutrophils loaded with drug nanoparticles and uses thereof |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025006799A1 (en) | 2023-06-27 | 2025-01-02 | Capstan Therapeutics, Inc. | Extracorporeal and ex vivo engineering of select cell populations from peripheral blood |
| CN116908455A (zh) * | 2023-07-25 | 2023-10-20 | 广西师范大学 | 一种检测癌胚抗原的光电化学免疫传感器的制备方法及其应用 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250144234A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics Inc. | RNA for In vivo Transfection with Increased Expression |
| AU2024372112A1 (en) * | 2023-11-03 | 2026-04-16 | Amgen Inc. | Fibroblast targeting molecules |
| US20250332281A2 (en) | 2023-12-15 | 2025-10-30 | Capstan Therapeutics, Inc. | Humanized anti-cd8 antibodies and uses thereof |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN119060202A (zh) * | 2024-08-12 | 2024-12-03 | 华中科技大学同济医学院附属协和医院 | 一种靶向fap的嵌合抗原受体调节性t细胞、其制备方法与应用 |
| CN119074926B (zh) * | 2024-08-29 | 2025-11-25 | 中国医学科学院阜外医院深圳医院(深圳市孙逸仙心血管医院) | 一种靶向fap的car-t细胞在制备治疗心肌炎慢性期心脏纤维化的药物中的应用 |
| CN119285786B (zh) * | 2024-10-15 | 2025-10-03 | 普飞(郑州高新技术产业开发区)生物科技有限公司 | 一种抗fap的纳米抗体及其应用 |
| CN119735700B (zh) * | 2024-11-25 | 2025-09-23 | 江苏集萃崛创生物科技研究所有限公司 | 一种car-t细胞及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1728800A (en) * | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| CA2412494C (en) | 2000-06-22 | 2012-10-23 | Genentech, Inc. | Agonist anti-trk-c monoclonal antibodies |
| CA2533593A1 (en) * | 2003-07-26 | 2005-02-10 | Biogen Idec Ma Inc. | Altered antibodies having improved antigen-binding affinity |
| KR20100110864A (ko) * | 2008-01-24 | 2010-10-13 | 노보 노르디스크 에이/에스 | 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체 |
| CA2776037A1 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| CA2806021C (en) | 2010-08-13 | 2019-05-21 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| CN103946952A (zh) * | 2011-09-16 | 2014-07-23 | 宾夕法尼亚大学董事会 | 用于治疗癌症的rna改造的t细胞 |
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| US20160136272A1 (en) | 2013-05-14 | 2016-05-19 | Innate Pharma | Methods for restoring corticosteroid sensitivity |
| SG11201601424PA (en) | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Site-specific antibody conjugation methods and compositions |
| AU2014317009A1 (en) | 2013-09-05 | 2016-03-10 | Aduro Biotech Holdings, Europe B.V. | CD70-binding peptides and method, process and use relating thereto |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| ES2857226T3 (es) | 2014-03-15 | 2021-09-28 | Novartis Ag | Receptor de antígeno quimérico regulable |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| RU2757314C2 (ru) | 2016-01-22 | 2021-10-13 | Мерк Шарп И Доум Корп. | Антитела против фактора свертывания xi |
| CN109715808A (zh) * | 2016-04-15 | 2019-05-03 | 诺华股份有限公司 | 用于选择性蛋白质表达的组合物和方法 |
| JP2018035137A (ja) * | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| CN107663240B (zh) * | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
| WO2018105560A1 (ja) | 2016-12-07 | 2018-06-14 | 国立大学法人大阪大学 | Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬 |
| JP7227912B2 (ja) | 2017-02-08 | 2023-02-24 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | キメラ抗原受容体の調節 |
| WO2019067425A1 (en) | 2017-09-26 | 2019-04-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES |
| CN109796532B (zh) | 2017-11-17 | 2024-09-10 | 恺兴生命科技(上海)有限公司 | 靶向成纤维激活蛋白α的结合单元及其应用 |
| MA51428A (fr) * | 2017-12-22 | 2020-11-04 | Bluebird Bio Inc | Récepteur d'antigène chimérique multivalent |
| EP3762030A4 (en) | 2018-03-09 | 2022-01-05 | Phanes Therapeutics, Inc. | ANTI-CD73 ANTIBODIES AND USES THEREOF |
| MX2022003465A (es) | 2019-09-23 | 2022-06-16 | Univ Pennsylvania | Anticuerpo monoclonal contra proteína de activación de fibroblasto canino de reacción cruzada con proteína de activación de fibroblasto (fap) de ratón y humana. |
| US12116418B2 (en) | 2019-09-23 | 2024-10-15 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| WO2022081694A1 (en) | 2020-10-13 | 2022-04-21 | The Trustees Of The University Of Pennsylvania | In vivo targeting of fibrosis by anti-cd5-targeted fap-car t mrna-lnp |
-
2020
- 2020-09-23 US US17/029,702 patent/US12116418B2/en active Active
- 2020-09-23 EP EP20870352.0A patent/EP4034554A4/en active Pending
- 2020-09-23 CA CA3151550A patent/CA3151550A1/en active Pending
- 2020-09-23 WO PCT/US2020/052227 patent/WO2021061778A1/en not_active Ceased
- 2020-09-23 BR BR112022005423A patent/BR112022005423A2/pt unknown
- 2020-09-23 MX MX2022003466A patent/MX2022003466A/es unknown
- 2020-09-23 KR KR1020227012360A patent/KR20220066312A/ko active Pending
- 2020-09-23 JP JP2022518209A patent/JP7621344B2/ja active Active
- 2020-09-23 CN CN202080079493.6A patent/CN114746438A/zh active Pending
- 2020-09-23 AU AU2020353000A patent/AU2020353000A1/en active Pending
-
2022
- 2022-03-14 IL IL291342A patent/IL291342A/en unknown
- 2022-03-25 ZA ZA2022/03511A patent/ZA202203511B/en unknown
-
2024
- 2024-07-18 US US18/776,496 patent/US20250011472A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548778A5 (enExample) | ||
| JP2022002546A (ja) | 細胞 | |
| JP7382829B2 (ja) | キメラ抗原受容体を発現するｔ細胞 | |
| AU2018360800A1 (en) | Chimeric antigen receptors specific for B-cell maturation antigen (BCMA) | |
| IL262321B1 (en) | Compositions and methods for selective protein expression | |
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| KR20230095083A (ko) | Cd7 표적의 키메라 항원 수용체 및 이의 용도 | |
| US20170015758A1 (en) | Compositions And Methods For Modulating And Redirecting Immune Responses | |
| WO2017165683A1 (en) | Cell secreted minibodies and uses thereof | |
| CA3016287A1 (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
| KR102316091B1 (ko) | Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도 | |
| RS66502B1 (sr) | Bispecifični ili-kapijski himerni antigenski receptor koji reaguje na cd19 i cd20 | |
| CN112638947A (zh) | 用于治疗实体瘤的嵌合抗原受体细胞 | |
| JP2022542559A5 (enExample) | ||
| CA3199205A1 (en) | Anti-bcma chimeric antigen receptors | |
| CA3103337A1 (en) | Nef-containing t cells and methods of producing thereof | |
| CN112074278A (zh) | Bcma-car-t细胞 | |
| CN112040957A (zh) | 靶向表达cd99的癌症的组合物和方法 | |
| JP2022547552A5 (enExample) | ||
| KR20210021593A (ko) | 다양한 구조 최적화를 갖는 t 세포-항원 커플러 | |
| CA3179348A1 (en) | Antibodies to nkp46 and constructs thereof for treatment of cancers and infections | |
| WO2023202280A1 (zh) | 抗B7H6的scFv抗体、其编码基因及其应用 | |
| JP2023516067A5 (enExample) | ||
| TW202309091A (zh) | 嵌合受體及其使用方法 | |
| AU2023390820A1 (en) | Chimeric antigen receptor |